Home » Topics » Drug design, drug delivery and technologies, BioWorld Science

Drug design, drug delivery and technologies, BioWorld Science
RSS

Bayer, CV Therapeutics collaborate on antiinflammatory drugs

May 24, 1996

Canadian health authorities commission LifeTECH labs

May 17, 1996

Xytronyx in-licenses LSAI technology

May 17, 1996

ArQule's AMAP system receives patent coverage

May 17, 1996

Three-way collaboration in cardiovascular field announced

May 17, 1996

Symbollon, Oclassen to codevelop dermatology products

May 17, 1996

Neuroprotective compounds target of new research agreement

May 17, 1996

Gensia, Pfizer to collaborate on ARA-based analgesics

May 17, 1996

Dyax phage display technology receives patent protection

May 10, 1996

CEPRATE SC approvable for autologous BMT

May 10, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...